A pedestrian walks past the NASDAQ building in New York City
A pedestrian walks past the NASDAQ building in New York City REUTERS

The top pre-market NASDAQ stock market gainers are: Radvision, Cytori Therapeutics, Allos Therapeutics, Pharmaceutical Product Development, ICAgen, and eBay. The top pre-market NASDAQ stock market losers are: MannKind, F5 Networks, Riverbed Technology, Isle of Capri Casinos, and Skyworks Solutions.

Gainers

Shares of Radvision Ltd. (RVSN) jumped 9.84 percent to $9.60 in the pre-market session.

Cytori Therapeutics, Inc. (CYTX) stock advanced 6.86 percent to $5.92 in the pre-market trading. The company said it got approval from The Netherlands to initiate a pivotal European trial named ADVANCE to investigate adipose-derived stem and regenerative cells, processed by the Celution One System, in the treatment of patients with acute heart attacks.

Cytori said ADVANCE is a randomized, placebo controlled, double-blind trial that will enroll up to 360 patients with ST-elevation myocardial infarction in up to 35 centers, predominately in Europe. The primary endpoint of the trial is reduction in infarct size as measured by cardiac magnetic resonance imaging.

Shares of Allos Therapeutics, Inc. (ALTH) gained 5.91 percent to $4.12 in the pre-market session. The company said the Journal of Clinical Oncology has published data from its pivotal Phase 2 PROPEL study demonstrating clinical activity of FOLOTYN (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The study results show an overall response rate of 29 percent observed in patients treated with FOLOTYN.

Pharmaceutical Product Development Inc. (PPDI) stock increased 5.52 percent to $30 in the pre-market trading. The company expects 2011 earnings of $1.53 to $1.69 a share and revenue, excluding reimbursed out-of-pocket expenses, of $1.48 billion to $1.58 billion. Analysts project profit of $1.48 a share on revenue of $1.49 billion.

Pharmaceutical Product Development expects first quarter earnings of 30 cents to 34 cents a share, while analysts project 35 cents a share. Second quarter earnings are forecast in the range of 36 cents to 40 cents a share, and third quarter earnings are projected in range of 41 cents to 45 cents a share. For the fourth quarter, earnings is expected between 46 cents and 50 cents a share.

Shares of ICAgen Inc. (ICGN) gained 4.08 percent to $3.06 in the pre-market session.

eBay Inc. (EBAY) stock rose 2.75 percent to $29.90 in the pre-market trading, following its better-than-expected fourth quarter earnings. Adjusted profit was $684 million or 52 cents a share, up from $586 million or 44 cents a share last year. Revenue rose 5 percent to $2.5 billion. Analysts had expected profit of 47 cents a share on revenue of $2.49 billion.

eBay expects first quarter adjusted earnings of 44 cents to 46 cents a share and revenue of $2.4 billion to $2.5 billion, while analysts project profit of 45 cents a share on revenue of $2.43 billion. The company anticipates full year 2011 adjusted profit of $1.90 to $1.95 a share and revenue of $10.3 billion to $10.6 billion, while Street expects profit of $1.85 a share on revenue of $10.19 billion.

Losers

MannKind Corp. (MNKD) stock lost 42.48 percent to $5.24 in the pre-market trading, as FDA has rejected its new drug application for Afrezza Inhalation Provider, a diabetic therapy. FDA asked the company to conduct two clinical trials of the inhaler, one in patients with type 1 diabetes and one in type 2 diabetes, with at least one trial including a treatment group using the MedTone inhaler for purpose of comparison.

MannKind's Afrezza is a novel, ultra rapid acting mealtime insulin therapy for the treatment of adult patients with type 1 and type 2 diabetes for the control of hyperglycemia. It is a drug-device combination product, consisting of Afrezza Inhalation Powder pre-metered into single use dose cartridges and Afrezza Inhaler.

Shares of F5 Networks, Inc. (FFIV) plunged 20.45 percent to $110.40 in the pre-market trading, after its first quarter revenue and forecast for second quarter sales missed analysts expectations. Adjusted profit for first quarter was $72.7 million or 88 cents a share, up from $41.4 million or 52 cents a share last year. Revenue grew 41 percent to $268.9 million. Analysts had expected profit of 83 cents a share on revenue of $270.34 million.

F5 Networks expects second quarter adjusted earnings of 84 cents to 86 cents a share and revenue of $275 million to $280 million. Street analysts expect earnings of 85 cents a share on revenue of $280.72 million.

Riverbed Technology, Inc. (RVBD) stock decreased 9.36 percent to $33.51 in the pre-market session.

F5 Networks' weak sales forecast knocked down network equipment stocks on concerns that the market for managing the explosion in Internet traffic may not be growing as fast as expected, according to Reuters. Shares of Cisco Systems, Inc. (CSCO) were down 0.43 percent, while those in Riverbed fell 9.36 percent in pre-market trading. Blue Coat Systems, Inc. (BCSI) slumped 7.19 percent and data center services provider Equinix Inc (EQIX) declined 0.79 percent.

Shares of Isle of Capri Casinos Inc. (ISLE) declined 6.94 percent to $10.05 in the pre-market trading, following its plan to sell 5.3 million shares of its common stock in an underwritten public offering. The company plans to use a portion of the net proceeds to temporarily repay borrowings outstanding under its revolving line of credit. The company also plans to use the balance proceeds for general corporate purposes including, without limitation, to finance future capital expenditures.

Skyworks Solutions Inc. (SWKS) stock moved down 5.99 percent to $30 in the pre-market session, ahead of its first quarter earnings release. Analysts are expecting Skyworks to earn 44 cents a share on revenue of $334.04 million for the first quarter.